OM
ASMB icon

Opaleye Management’s Assembly Biosciences ASMB Stock Holding History

Opaleye Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,167
Closed -$492K – 48
2019
Q3 		$492K Buy
+4,167
New +$630K 0.18% 47

Other funds holding ASMB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Opaleye Management's ASMB Position: Q4 2019 in Review

Opaleye Management sold out of Assembly Biosciences (ASMB) in Q4 2019, closing a stake of 4,167 shares — an estimated $492K sold.

Opaleye Management first reported a position in ASMB in Q3 2019 and held it in 1 quarter. The position peaked at $492K in Q3 2019. 100 funds tracked by Wall St. Rank hold ASMB as of Q4 2019.

  • Opaleye Management reported no remaining Assembly Biosciences position as of Q4 2019 after selling out during the quarter.
  • Opaleye Management sold 4,167 Assembly Biosciences shares in Q4 2019, an estimated $492K.
  • Opaleye Management first reported a position in Assembly Biosciences in Q3 2019 and held it in 1 quarter.
  • Opaleye Management's Assembly Biosciences position peaked at $492K in Q3 2019.
  • 100 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2019.

Based on Opaleye Management's 13F filing for Q4 2019, filed 14 Feb 2020.